HIVe Home
HIV VACCINE ELECTRONIC (E) RESOURCE

HIVe Frequently Asked Questions

What is HIVe?

HIVe (HIV Vaccine electronic (e) resource) is a centralized, online resource for the HIV vaccine research community, developed and hosted by the Global HIV Vaccine Enterprise (Enterprise).  HIVe helps connect the global community of HIV vaccine researchers, with a focus on the needs and interests of young and early-career investigators, by providing up-to-date information about funding and employment opportunities, events, training courses, workshops, and other activities.  HIVe also serves as a forum for discussion of the most pressing issues in the field, and as a virtual meeting place for all individuals involved in HIV vaccine research worldwide.

How do I find HIVe?

HIVe can be accessed directly at www.vaccineenterprise.org/HIVe, and via links on the Global HIV Vaccine Enterprise homepage and the homepages of many Enterprise stakeholders. 

Is HIVe only for young and early career investigators?

No.  HIVe is for everyone involved in the search for a safe and effective HIV vaccine.  HIVe includes the latest on jobs, grants and scholarships; events and training opportunities; HIV vaccine research news and researcher profiles; guest commentators; and an open forum for the debate of controversial issues in the field.  While young and early-career investigators will find many HIVe resources particularly useful, everyone involved in HIV vaccine research will want to bookmark HIVe and visit often for the latest news and information.

How can I contribute to the HIVe?

The HIVe is a highly interactive site.  Your participation is encouraged in HIVe forums and discussions.  You can submit opinion pieces, research news, funding opportunities and event and job announcements to the HIVe at HIVe@vaccineenterprise.org.  In addition, we welcome your ideas for forum topics or proposals for HIV guest speakers or commentators.  Contact us with your ideas for HIVe at HIVe@vaccineenterprise.org.

Why was HIVe created?

HIVe was created in response to the 2010 Scientific Strategic Plan of the Global HIV Vaccine Enterprise (Plan), a collaborative framework to accelerate HIV vaccine research and development.  The Plan calls for new strategies to recruit and retain the best young and early-career investigators to HIV vaccine research, including new efforts to redefine traditional mentorship, training, and career development; improve access to data and resources; help researchers secure funding, laboratory space, and academic positions; increase the visibility and leadership representation of YECIs in HIV vaccine research; and help YECIs in the developing world overcome funding, institutional and career development challenges.